In the past decade, many scientific breakthroughs have been achieved in the treatment of cancer through basic research. This meeting will discuss that latest paradigm shift: personalised immunotherapies in combination with other drugs for the treatment of cancer. This shift is taking place against a backdrop of the development and regulatory approval of new monoclonal antibodies, cancer vaccines, adoptive cell therapies and immune-checkpoint therapies.
